
GEHC Stock Forecast & Price Target
GEHC Analyst Ratings
Bulls say
GE HealthCare Techs is expected to experience organic revenue growth of 3.5% in the next year due to its leading market share and diverse sales channels in the medical technology industry. Its strong backlog growth with a 2-quarter lag suggests efficient conversion into organic revenue, and its correlation with orders and book-to-bill ratios provides reliable metrics for near-term visibility. While there are risks such as increasing competition and trade dynamics, potential upside factors include reduced competition, rapid integration of recent mergers and acquisitions, and new product growth.
Bears say
GE HealthCare Techs is facing challenges due to a slower turnaround time in converting its backlog into revenue, which reflects delays in organic revenue recognition for products such as Ultrasound units, handheld devices, and Patient Care Solutions due to supply chain-related issues. Additionally, the company's new product launches and increased competition in certain sub-markets are key factors that could impact its future performance. Furthermore, the recent approval of a generic version of its core product Omnipaque may also lead to potential market share loss and decrease its revenue in the Pharmaceutical Diagnostics segment.
This aggregate rating is based on analysts' research of GE HealthCare Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
GEHC Analyst Forecast & Price Prediction
Start investing in GEHC
Order type
Buy in
Order amount
Est. shares
0 shares